These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15531409)

  • 1. Program to improve cognitive functioning in patients with schizophrenia: reflections.
    Scolnick E
    Schizophr Res; 2004 Dec; 72(1):75-7. PubMed ID: 15531409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MATRICS initiative: developing a consensus cognitive battery for clinical trials.
    Green MF; Nuechterlein KH
    Schizophr Res; 2004 Dec; 72(1):1-3. PubMed ID: 15531401
    [No Abstract]   [Full Text] [Related]  

  • 3. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
    Marder SR; Fenton W
    Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive deficits as treatment targets in schizophrenia.
    Gold JM
    Schizophr Res; 2004 Dec; 72(1):21-8. PubMed ID: 15531404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.
    Green MF; Kern RS; Heaton RK
    Schizophr Res; 2004 Dec; 72(1):41-51. PubMed ID: 15531406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
    Kern RS; Green MF; Nuechterlein KH; Deng BH
    Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cognitive deficits in schizophrenia.
    Bowie CR; Harvey PD
    Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
    Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
    Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of separable cognitive factors in schizophrenia.
    Nuechterlein KH; Barch DM; Gold JM; Goldberg TE; Green MF; Heaton RK
    Schizophr Res; 2004 Dec; 72(1):29-39. PubMed ID: 15531405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative.
    Marder SR; Fenton W; Youens K
    Am J Psychiatry; 2004 Jan; 161(1):25. PubMed ID: 14702244
    [No Abstract]   [Full Text] [Related]  

  • 14. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients.
    Fujii DE; Ahmed I; Jokumsen M; Compton JM
    J Neuropsychiatry Clin Neurosci; 1997; 9(2):240-5. PubMed ID: 9144103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functionality as a goal in the treatment of schizophrenia].
    García B;
    Actas Esp Psiquiatr; 2002; 30(5):312-25. PubMed ID: 12372228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
    Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
    Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment.
    Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M
    Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.